ArcaScience

📍 Paris, France🗓 Founded 2018👥 27 employees💰 Last funded Jul 2025
Software Development🌐 arcascience.ai
Website LinkedIn
ArcaScience is setting the new standard for Benefit–Risk Assessment, leveraging AI to turn clinical uncertainty into up to +5% approval success. Our AI-Benefit-Risk Solution is the first to be fully aligned with CIOMS and ICH guidelines, featuring: > Regulatory-ready: BRA exports are compliant with CIOMS/FDA/EMA, ready for submission to regulatory agencies > Full expert control: every AI-generated item can be reviewed, edited, and validated by the expert > Cross-functional collaboration: pharmacovigilance, clinical, regulatory, and medical affairs teams work on a single shared platform across the entire drug lifecycle > AI-powered synthesis: automated identification, extraction, and structuring of clinical and safety data > 100% sourced, no hallucination: full traceability on every data point The Impact: We reduce BRA timelines from 3–8 months to just 2–3 days, deliver +5% market access, and provide best-in-class candidate optimization both during and after clinical trials.
10
Total investors
0
Early stage
0
Mid stage
10
Late stage
2018
Founded

Investors

10 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Italy
6
France
4
Frequently asked questions
Who invested in ArcaScience?
ArcaScience has 10 investors on record on gritt.io and 10 late-stage investors.
When did ArcaScience last raise funding?
The most recent investment in ArcaScience recorded on gritt.io was in July 2025.
When was ArcaScience founded?
ArcaScience was founded in 2018.
What industry is ArcaScience in?
ArcaScience operates in Software Development. Find similar Software Development investors on gritt.io.
Where is ArcaScience based?
ArcaScience is headquartered in Paris, France.